News
Bausch Health's Aplenzin shows promise for treatment-resistant depression (TRD), potentially offering better efficacy and tolerability compared to Wellbutrin, addressing a significant unmet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback